Misinformation Surge Threatens Vaccine Confidence, WHO Experts Warn

Vaccine Programs Face Growing Challenges from Misinformation and Funding Uncertainties

Vaccine programs worldwide are confronting a dual threat of rising misinformation and uncertain research funding, according to experts from the World Health Organization’s immunization advisory group.

The WHO’s Strategic Advisory Group of Experts on Immunisation (SAGE), which recently concluded its biannual meeting, warned that ongoing conflicts in the Middle East could significantly hamper global efforts to eradicate polio. The meeting addressed critical issues including COVID-19 vaccination recommendations, typhoid vaccine dosing schedules, and oral polio vaccine protocols.

“Emerging challenges for the future include uncertain funding for vaccine research and development, and misinformation and distorted information that erodes public trust in vaccines,” the group stated in its assessment. “Protecting trust and countering misinformation will be a central focus in 2026.”

Kate O’Brien, WHO’s vaccines chief, emphasized that resources would be directed this year toward safeguarding core immunization programs. “We’re in a really deeply changing world for infectious diseases and for vaccine programmes,” she noted, citing conflicts, economic challenges, and reductions in health budgets as contributing factors.

The spread of vaccine misinformation presents a particular challenge to public health initiatives. In the United States, health chief Robert F. Kennedy Jr. has been criticized for promoting anti-vaccine rhetoric and making unsubstantiated claims connecting vaccines to autism. In response to such claims, a December WHO review of all available evidence reaffirmed that no link exists between vaccines and autism.

“Vaccines do not cause autism and they never have caused autism,” O’Brien stressed, highlighting that vaccines have saved an estimated 154 million lives over the past five decades and can prevent more than 30 different diseases.

The risk of backsliding on immunization progress looms large, with concerns that countries might reduce their vaccine programs due to financial constraints. This potential regression comes at a critical time for global disease prevention efforts.

Polio eradication faces significant hurdles, with ongoing transmission of wild poliovirus in Pakistan and Afghanistan, as well as persistent detection of vaccine-derived type-2 poliovirus in several African nations. The latter strain is related to the weakened live poliovirus contained in oral polio vaccines.

SAGE chair Anthony Scott expressed concern that Middle East conflicts could lead to further dissemination of polioviruses, complicating eradication goals. O’Brien contrasted spending priorities globally, noting: “There are billions and billions of dollars being spent, day in and day out to destroy lives through wars. Does the world have its priorities straight about what we’re investing in?”

Regarding COVID-19 vaccination strategies, SAGE recommended that countries consider routine vaccination twice yearly for high-risk groups, citing diminishing protection beyond six months. The COVID-19 vaccine market has contracted to a limited number of manufacturers and types, with mRNA vaccines remaining dominant.

O’Brien called for increased investment in vaccine research, particularly for developing pan-coronavirus vaccines that could address multiple coronavirus threats beyond just COVID-19. Additionally, she emphasized the need for longer-lasting injections that would reduce the burden of repeat vaccinations on healthcare systems and vulnerable populations, especially the elderly.

Research and development funding patterns typically follow major disease outbreaks, creating what O’Brien described as “this cycle of crisis and response” rather than sustained investment in prevention.

Annelies Wilder-Smith, SAGE executive secretary, highlighted the urgent need for improved COVID vaccines that have greater impact on mild disease and can more effectively reduce transmission of the virus.

As these challenges continue to evolve, global health organizations face the complex task of maintaining vaccine confidence and access amid changing geopolitical landscapes and information environments.